Search Results for: GNPX

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it was added to the Russell 3000(R) Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution. “Genprex is excited to be a member of … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Joins Russell 3000(R) Index”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that the United States Adopted Names (“USAN”) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex(TM) immunogene therapy, the Company’s lead drug candidate for non-small cell lung cancer (“NSCLC”). “The USAN’s … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Another Step in Advancement of Lead Drug Candidate for NSCLC”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that its CEO and Chairman, Rodney Varner, will be participating in a live interview with the “Big Biz Show,” an Emmy Award winning nationally syndicated TV and radio show, on Thursday, June 25. The Big … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Participate Live on “The Big Biz Show””

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s program for the manufacture of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for its lead drug candidate, Oncoprex(TM) immunogene therapy. … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) and Aldevron Expand Manufacturing Program to Advance Oncoprex(TM)”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell 3000 Index, which includes the 3,000 publicly traded companies on the Nasdaq and NYSE exchanges with the largest market capitalizations. According to the update and … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Selected to Join Russell 3000(R) Index”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will present at the MoneyShow June Virtual Event at 12:50 p.m. EDT on Wednesday, June 10, 2020. According to the update, Genprex’s CEO and Chairman, Rodney Varner, will deliver a company overview and … Continue reading “QualityStocksNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Chairman and CEO to Present at the MoneyShow June Virtual Event”

Genprex (NASDAQ: GNPX) today announced the exercise of warrants to purchase approximately 5.4 million shares of common stock issued in connection with capital raises in May 2018 and November 2019 with two institutional investors at a price of $0.46 per share, resulting in its receipt of approximately $2.5 million in cash proceeds. According to the … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Secures $2.5 Million in Cash Proceeds from Recent Warrant Exercises”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it has entered into a patent and technology license agreement with The University of Texas MD Anderson Cancer Center, granting Genprex an exclusive worldwide license to a portfolio of 16 patent applications and related … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Expands Oncology Franchise via Exclusive Worldwide Patent and Technology License Agreement”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights the Company’s progress with Oncoprex(TM), its lead drug candidate with an initial targeted indication for non-small cell lung cancer (“NSCLC”), … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Shareholder Letter Highlighting Oncoprex(TM) Progress, License Agreement for a Diabetes Drug Candidate and Other Achievements”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Shannon Inman as Vice President of Global Clinical Operations. According to the update, Inman will lead in defining clinical developmental strategies, clinical protocol design, study conduct, and managing risk assessment in this … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Accomplished Executive Shannon Inman to Drive Launch of Key Clinical Trials”